Key Takeaways
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY.
UBS has beat EPS estimates in the last four quarters by an average of 53%, driven by wealth management inflows and cost savings from Credit Suisse integration.
HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Both banks target mid-teens RoTE, with UBS advancing Credit Suisse integration, and HSBC focusing on Asia wealth expansion and cost discipline.
UBS emphasizes Swiss precision in wealth and investment banking, while HSBC leverages global scale, especially in Hong Kong and Asia.
Investor focus: UBS on integration milestones, HSBC on NII trajectory amid evolving interest rates.
Earnings Context and Why It Matters
UBS’s Q4 report closes a transformative year post-Credit Suisse acquisition, with investors monitoring progress on $13 billion in gross cost savings and non-core asset wind-downs. Despite a revenue dip from elevated prior-year levels, EPS growth is expected, supported by strong wealth inflows and a rebound in investment banking.
HSBC’s Q4 report highlights a different strategy: a global universal bank with a strong Asian focus. Comparing UBS and HSBC underscores diverging paths in European banking—UBS’s wealth-centric Swiss model versus HSBC’s diversified, Asia-driven approach. Both face geopolitical and interest rate pressures, but UBS’s integration execution and HSBC’s NII expansion showcase sector resilience, providing investors insight into European banking stability amid global volatility.
UBS: Earnings in Focus
Consensus EPS: $0.25–$0.67 (TipRanks median $0.54) vs. $0.23 last year.
Revenue: ~$11.62 billion, down YoY.
Key metrics:
Global Wealth Management net new assets (Q3: $38B quarterly)
Cumulative cost savings: $9.1B toward $13B target
CET1 ratio: ~14%
Non-Core/Legacy RWA reduction: Target < $8B by 2025-end
Investment banking revenues may benefit from solid Q4 deal flow. Historically, UBS has beat estimates by 53% on average, with stock reactions mixed (e.g., -2% post-Q3). Management guidance emphasizes completion of 2026 integration, supporting a ~15% RoCET1 target.
HSBC: Context and Earnings Relevance
Q4 consensus EPS: ~$1.57 vs. $1.45 prior.
Q3 highlights: Revenue $17.9B (+3% YoY), pre-tax profit $7.3B despite $1.4B legal provisions, NII +15% to $8.8B, and YTD RoTE 17.6% ex-notables.
Strategy emphasizes four core businesses (Hong Kong, UK, CIB, Wealth/Premier), mid-single-digit cost growth, and Hang Seng privatization.
HSBC’s emerging market exposure contrasts with UBS’s premium Swiss wealth focus. Both prioritize capital returns through dividends and buybacks.
Head-to-Head Earnings and Market Comparison
Scale and focus: HSBC ~$63B trailing revenue vs. UBS ~$39B, but UBS delivers higher margins in wealth management (Q3 NNA $92B YTD) vs. HSBC’s volume-driven growth.
Earnings quality: UBS average EPS surprise 53%, HSBC consistently strong ex-notables.
Growth drivers: UBS’s Credit Suisse synergies (70% of cost saves achieved); HSBC’s Asia pivot (wealth fees double-digit medium-term growth).
Risks: UBS faces legacy litigation and integration challenges; HSBC contends with property exposure (Hang Seng NPLs).
Valuation and sentiment: UBS trades at a premium, reflecting transformation progress, while HSBC remains a steady execution play amid interest rate sensitivity.
Tickeron AI Perspective
Tickeron AI Verdict
Tickeron’s AI models currently favor UBS, citing:
Superior earnings surprise history
Accelerating cost efficiencies
Positioned growth in high-margin wealth and investment banking
HSBC offers scale and NII resilience, but UBS’s integration execution and RoCET1 trajectory give it a probabilistic edge for outperformance, assuming no major shocks.
Disclaimers and Limitations
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
UBS saw its Momentum Indicator move below the 0 level on August 21, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 76 similar instances where the indicator turned negative. In of the 76 cases, the stock moved further down in the following days. The odds of a decline are at .
The Moving Average Convergence Divergence Histogram (MACD) for UBS turned negative on July 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UBS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where UBS advanced for three days, in of 347 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 322 cases where UBS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 20, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. UBS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.830) is normal, around the industry mean (1.897). UBS has a moderately high P/E Ratio (18.126) as compared to the industry average of (15.307). Projected Growth (PEG Ratio) (0.869) is also within normal values, averaging (1.603). Dividend Yield (0.021) settles around the average of (0.026) among similar stocks. P/S Ratio (3.392) is also within normal values, averaging (3.937).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a major bank
Industry MajorBanks